Photo by Luis ROBAYO / AFP
MANILA, Philippines — The manufacturer of ivermectin said that the studies related to the controversial drug have “concerning lack of safety data,” explaining that the drug shows no promise against COVID-19.
“We do not believe that the data available support the safety and efficacy of ivermectin beyond the doses and populations indicated in the regulatory agency-approved prescribing information,” said Merck in a statement in February.
However, it’s gaining popularity as a supposed treatment and prophylaxis (preventative medicine) in the country.
Two lawmakers distributed the drug to the poor on Thursday under the guise of a community pantry, despite a warning from health agencies.
READ: WATCH: Defensor, Marcoleta lead ivermectin distribution in Quezon City
On Wednesday, the Department of Health said that only hospitals with a compassionate special permit to administer human-grade ivermectin for COVID-19 treatment are allowed to distribute the drug.
READ: DOH: Only hospitals with permit to use ivermectin can distribute the drug
So far, only five hospitals have been granted the CSP, according to the Food and Drug Administration (FDA).
READ: FDA: 2 more hospitals may use ivermectin vs COVID-19
Only topical creams containing ivermectin used for treating head lice and rosacea skin ailments are commercially available in the Philippines.
RELATED STORIES
Defensor, et al. can use loophole to dodge Ivermectin lawsuit – DOJ
Philippines to conduct clinical trials on ivermectin as COVID-19 treatment
DOH, DOST urged: Speed up study on ivermectin use vs COVID-19